2 April 2026 in Journal of Clinical Psychopharmacology
Background: Long-acting injectable (LAI) antipsychotics improve adherence and reduce relapse in severe mental illnesses. A new two-injection start (TIS) regimen of aripiprazole monohydrate LAI has recently been introduced as an alternative to the standard initiation regimen. Evidence on its clinical benefits, particularly in females with schizophrenia or bipolar disorder, remains limited. Methods: This retrospective cohort study included 87 female inpatients diagnosed with schizophrenia or bipolar disorder. Participants were divided into two groups according to initiation protocol: The standard regimen (400 mg injection plus 14 days of oral aripiprazole) or the TIS regimen (two 400 mg injections with a single 20 mg oral dose). Clinical outcomes were compared between groups, including time to discharge, rehospitalization rates, and symptom change. Results: Of the total sample, 47 patients received the TIS regimen and 40 the standard regimen. Baseline demographic and clinical features were comparable between groups. Time to discharge was significantly shorter in the TIS regimen group (mean 8.1 vs. 11.8 d, P = 0.042). Rehospitalization rates within 1 year were lower in the TIS regimen group (17.0% vs. 37.5%, P = 0.031), and time to rehospitalization was longer ( P = 0.027). Adherence patterns favored the TIS regimen, with a higher proportion of regular use. In the schizophrenia subgroup, PANSS reductions from admission to discharge were greater with the TIS regimen. Adverse events were infrequently documented. Conclusions: Aripiprazole monohydrate LAI initiation with the TIS regimen was associated with shorter hospitalization and more favorable rehospitalization outcomes compared with the standard protocol in female patients.
1 January 2025 in Dusunen Adam: Journal of Psychiatry and Neurological Sciences
Objective: Schizophrenia is a chronic psychiatric disorder frequently complicated by nonadherence to oral antipsychotics. Long-acting injectable antipsychotics (LAIA) improve adherence and reduce relapse, yet their use differs across countries. This study examined the knowledge, attitudes, and prescribing practices of psychiatrists in Türkiye regarding LAIA treatments. Method: A cross-sectional online survey was conducted between March 2024 and March 2025. The questionnaire, distributed to 1,255 psychiatrists, collected sociodemographic data, clinical workload, and responses to 13 attitude statements. A total of 157 psychiatrists completed the survey and met inclusion criteria. Descriptive statistics and chi-square analyses were performed to assess associations between attitudes and demographic or institutional characteristics. Results: Participants had a mean age of 38 years; 72.6% were female. Most respondents (79.6%) reported routinely considering LAIA therapy. Paliperidone (80.3%) and aripiprazole (47.8%) were the most frequently preferred agents. Positive attitudes were more common among psychiatrists with longer professional experience and those working in institutions with inpatient clinics. More experienced clinicians were significantly less likely to endorse misconceptions, such as the belief that LAIAs limit therapeutic relationships, are costlier than hospitalization, or represent an unpleasant treatment for patients. Attitudes varied across workplace settings: private sector psychiatrists more often expressed caution, particularly regarding first-episode psychosis. Conclusion: Psychiatrists in Türkiye generally recognize the value of LAIAs beyond nonadherent cases, with professional experience and institutional context shaping prescribing patterns. While favorable attitudes predominate, misconceptions and systemic barriers persist. Targeted education, supportive policies, and shared decision-making strategies may promote wider, evidence-based use of LAIAs in clinical practice.
12 August 2026 in Psychiatry and Clinical Psychopharmacology
Background: Time perception, which has been conceptualized as a distinct sensory modality in some models, has been investigated in various psychiatric disorders. There is evidence suggesting impairments in time perception tasks among individuals diagnosed with schizophrenia and depressive disorder. This study aimed to examine the relationship between time estimation, production task performance, and both psychotic and depressive symptoms in patients with schizophrenia.Methods: A total of 50 patients diagnosed with schizophrenia and 50 healthy controls were administered structured time estimation and time production tasks at varying intervals. Additionally, the Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) were used for symptom assessment and correlational analyses.Results: In exploratory unadjusted analyses, significant group differences were observed at the 1-, 13-, and 32-second time estimation intervals. In the primary adjusted analyses controlling for age and smoking status, significant group differences remained at the 13-second and 32-second intervals. No significant group differences were observed for any time production interval.Conclusion: In this stabilized inpatient sample, patients with schizophrenia exhibited significantly greater time-estimation errors at the 13-second and 32-second intervals in the primary adjusted analyses, whereas time-production performance did not differ significantly from that of healthy controls. The absence of statistically significant associations with psychotic or depressive symptom scores suggests that timing performance may be partly independent of current symptom severity; longitudinal studies are needed to determine whether these abnormalities represent trait-like characteristics.